DeepMed Research

BioNTech

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Employees: 6.1K

Market Cap: $20.7B

Website: http://www.biontech.de

Introduction: BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Clinical Trials

A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm

Phase 2

Not yet recruiting

Conditions: Testicular Germ Cell Tumor
Extragonadal Germ Cell Tumor

Interventions: Biological: CLDN6 CAR-T
Biological: CLDN6 RNA-LPX

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: BioNTech SE

Target Recruit Count: 150

Registration Number: NCT06940804

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Phase 1

Recruiting

Conditions: Advanced Lung Cancer

Interventions: Biological: BNT324
Biological: BNT327

First Posted Date: 2025-03-24

Last Posted Date: 2025-05-13

Lead Sponsor: BioNTech SE

Target Recruit Count: 594

Registration Number: NCT06892548

Locations: 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: BNT327
Drug: Docetaxel

First Posted Date: 2025-02-24

Last Posted Date: 2025-03-18

Lead Sponsor: BioNTech SE

Target Recruit Count: 60

Registration Number: NCT06841055

Locations: 🇺🇸
Millennium Research and Clinical Development, LLC, Houston, Texas, United States

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Phase 1

Recruiting

Conditions: Advanced Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: BNT323
Drug: BNT327

First Posted Date: 2025-02-14

Last Posted Date: 2025-05-14

Lead Sponsor: BioNTech SE

Target Recruit Count: 320

Registration Number: NCT06827236

Locations: 🇺🇸
Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States
🇲🇩
Institute of Oncology Arensia Exploratory Medicine, Chisinau, Moldova, Republic of

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

Phase 1

Recruiting

Conditions: Influenza
COVID-19 (Coronavirus Disease 2019)

Interventions: Biological: Investigational COVID-19 Vaccine
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Biological: Investigational Influenza Vaccine
Biological: Licensed COVID-19 Vaccine
Biological: Licensed Influenza Vaccine 2
Biological: Licensed Influenza Vaccine 1
Biological: Licensed Influenza Vaccine 3

First Posted Date: 2025-02-11

Last Posted Date: 2025-03-18

Lead Sponsor: BioNTech SE

Target Recruit Count: 2050

Registration Number: NCT06821061

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States

and more 22 locations

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Biological: BNT317 DL1
Biological: BNT317 DL2
Biological: BNT317 DL3
Biological: BNT317 DL4
Biological: BNT317 DL5 (intermediate)
Biological: BNT317 DL6 (intermediate)
Biological: BNT317 DL7 (additional)

First Posted Date: 2024-12-27

Last Posted Date: 2025-02-06

Lead Sponsor: BioNTech SE

Target Recruit Count: 39

Registration Number: NCT06750185

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
Carolina BioOncology Institute, LLC, Huntsville, North Carolina, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 1 locations

Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Phase 3

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: BNT327
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2024-12-02

Last Posted Date: 2025-04-01

Lead Sponsor: BioNTech SE

Target Recruit Count: 439

Registration Number: NCT06712355

Locations: 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Australia
🇬🇧
St James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

and more 6 locations

Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: BNT327
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2024-12-02

Last Posted Date: 2025-05-16

Lead Sponsor: BioNTech SE

Target Recruit Count: 982

Registration Number: NCT06712316

Locations: 🇺🇸
Alaska Oncology and Hematology, LLC, Anchorage, Alaska, United States
🇺🇸
Clermont Oncology Center, Clermont, Florida, United States
🇺🇸
Physicians Clinic of Iowa, Cedar Rapids, Iowa, United States

and more 44 locations

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

Phase 1

Active, not recruiting

Conditions: Influenza,Human
COVID-19

Interventions: Biological: COVID-19 Vaccine
Biological: Investigational Influenza Vaccine
Combination Product: Influenza and COVID Combination Vaccine
Other: Placebo
Biological: Licensed Influenza Vaccine 1
Biological: Licensed Influenza Vaccine 2

First Posted Date: 2024-11-12

Last Posted Date: 2025-01-31

Lead Sponsor: BioNTech SE

Target Recruit Count: 1353

Registration Number: NCT06683352

Locations: 🇺🇸
Clinical Research Professionals, Chesterfield, Missouri, United States
🇺🇸
Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield, Missouri, United States
🇺🇸
Orange County Research Center, Lake Forest, California, United States

and more 19 locations

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

Phase 1

Active, not recruiting

Conditions: Bacterial Vaginosis

Interventions: Drug: BNT331
Other: Placebo

First Posted Date: 2024-06-21

Last Posted Date: 2025-04-17

Lead Sponsor: BioNTech SE

Target Recruit Count: 102

Registration Number: NCT06469164

Locations: 🇺🇸
UAB Sexual Health Research Clinic, Birmingham, Alabama, United States
🇺🇸
Praetorian Pharmaceutical Research, LLC, Marrero, Louisiana, United States
🇺🇸
Southern Clinical Research Associates - Metairie, Metairie, Louisiana, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy